Last reviewed · How we verify

Carcinoma of female breast — Treatment Landscape & Competitive Intelligence

Carcinoma of female breast (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Carcinoma of female breast, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Nolvadex tamoxifen AstraZeneca (originally ICI) SERM (Selective estrogen receptor modulator) Aldehyde oxidase, 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase, 5-hydroxytryptamine receptor 6 1977-12-30
Doxorubicin Hydrochloride doxorubicin Pfizer Anthracycline Topoisomerase Inhibitor Aurora kinase A 1974-01-01
Liposomal Doxorubicin liposomal-doxorubicin Pfizer doxorubicin 72 kDa type IV collagenase 1974-01-01
Trexall methotrexate Generic (originally Lederle Laboratories) Antifolate, DMARD Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4 1953-12-07
Adriamycin Adriamycin Johann Wolfgang Goethe University Hospital Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase
Vinblastin Vinblastin The Lymphoma Academic Research Organisation Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1
Methotrexat Methotrexat Biocad Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4
Hydroxydaunorubicin Hydroxydaunorubicin University of Colorado, Denver Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase
Hydroxydaunomycin Hydroxydaunomycin Weill Medical College of Cornell University Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase
adriacin adriacin Chipscreen Biosciences, Ltd. Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 2 drugs in Carcinoma of female breast
  2. · 2 drugs in Carcinoma of female breast
  3. Biocad · 1 drug in Carcinoma of female breast
  4. Chipscreen Biosciences, Ltd. · 1 drug in Carcinoma of female breast
  5. Generic (originally Lederle Laboratories) · 1 drug in Carcinoma of female breast
  6. Johann Wolfgang Goethe University Hospital · 1 drug in Carcinoma of female breast
  7. The Lymphoma Academic Research Organisation · 1 drug in Carcinoma of female breast
  8. University of Colorado, Denver · 1 drug in Carcinoma of female breast
  9. Weill Medical College of Cornell University · 1 drug in Carcinoma of female breast
  10. AstraZeneca (originally ICI) · 1 drug in Carcinoma of female breast

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Carcinoma of female breast:

Cite this brief

Drug Landscape (2026). Carcinoma of female breast — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/carcinoma-of-female-breast. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing